Prognostic evidence of LEF1 isoforms in childhood acute lymphoblastic leukemia
Yucel Erbilgin
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
Search for more papers by this authorOzden Hatirnaz Ng
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
Faculty of Medicine, Department of Medical Biology, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
Search for more papers by this authorIsmail Can
Institute of Health Sciences, Istanbul University, Istanbul, Turkey
Search for more papers by this authorSinem Firtina
Institute of Health Sciences, Istanbul University, Istanbul, Turkey
Faculty of Art and Science, Department of Molecular Biology and Genetics, Istinye University, İstanbul, Turkey
Search for more papers by this authorFulya Kucukcankurt
Institute of Health Sciences, Istanbul University, Istanbul, Turkey
Faculty of Medicine, Altınbaş University, Istanbul, Turkey
Search for more papers by this authorSerap Karaman
Istanbul Faculty of Medicine, Pediatric Hematology Oncology Department, Istanbul University, Istanbul, Turkey
Search for more papers by this authorZeynep Karakas
Istanbul Faculty of Medicine, Pediatric Hematology Oncology Department, Istanbul University, Istanbul, Turkey
Search for more papers by this authorTulin Tiraje Celkan
Pediatric Hematology Oncology Department, Istanbul University-Cerrahpasa Faculty of Medicine, Istanbul, Turkey
Search for more papers by this authorEmine Zengin
Faculty of Medicine, Department of Pediatric Hematology, Kocaeli University, Kocaeli, Turkey
Search for more papers by this authorSema Aylan Gelen
Faculty of Medicine, Department of Pediatric Hematology, Kocaeli University, Kocaeli, Turkey
Search for more papers by this authorGul Nihal Ozdemir
Pediatric Hematology Division, Istanbul Kanuni Sultan Suleyman Education and Research Hospital, Istanbul, Turkey
Search for more papers by this authorYildiz Yildirmak
Pediatric Hematology Division, Ministry of Health Sisli Etfal Education and Research Hospital, Istanbul, Turkey
Search for more papers by this authorOmer Dogru
Pediatric Hematology and Oncology Department, Marmara University School of Medicine, Istanbul, Turkey
Search for more papers by this authorTurkan Tansel
Istanbul Medical Faculty, Department of Cardiovascular Surgery, Istanbul University, Istanbul, Turkey
Search for more papers by this authorKhusan Khodzhaev
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
Institute of Health Sciences, Istanbul University, Istanbul, Turkey
Search for more papers by this authorOzlem Toluk
Department of Biostatistics and Medical Informatics, Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey
Search for more papers by this authorUgur Ozbek
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
Faculty of Medicine, Department of Medical Genetics, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
Search for more papers by this authorCorresponding Author
Muge Sayitoglu
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
Correspondence
Muge Sayitoglu, Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Vakif Gureba Cad. 34093, Istanbul, Turkey.
Email: [email protected]
Search for more papers by this authorYucel Erbilgin
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
Search for more papers by this authorOzden Hatirnaz Ng
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
Faculty of Medicine, Department of Medical Biology, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
Search for more papers by this authorIsmail Can
Institute of Health Sciences, Istanbul University, Istanbul, Turkey
Search for more papers by this authorSinem Firtina
Institute of Health Sciences, Istanbul University, Istanbul, Turkey
Faculty of Art and Science, Department of Molecular Biology and Genetics, Istinye University, İstanbul, Turkey
Search for more papers by this authorFulya Kucukcankurt
Institute of Health Sciences, Istanbul University, Istanbul, Turkey
Faculty of Medicine, Altınbaş University, Istanbul, Turkey
Search for more papers by this authorSerap Karaman
Istanbul Faculty of Medicine, Pediatric Hematology Oncology Department, Istanbul University, Istanbul, Turkey
Search for more papers by this authorZeynep Karakas
Istanbul Faculty of Medicine, Pediatric Hematology Oncology Department, Istanbul University, Istanbul, Turkey
Search for more papers by this authorTulin Tiraje Celkan
Pediatric Hematology Oncology Department, Istanbul University-Cerrahpasa Faculty of Medicine, Istanbul, Turkey
Search for more papers by this authorEmine Zengin
Faculty of Medicine, Department of Pediatric Hematology, Kocaeli University, Kocaeli, Turkey
Search for more papers by this authorSema Aylan Gelen
Faculty of Medicine, Department of Pediatric Hematology, Kocaeli University, Kocaeli, Turkey
Search for more papers by this authorGul Nihal Ozdemir
Pediatric Hematology Division, Istanbul Kanuni Sultan Suleyman Education and Research Hospital, Istanbul, Turkey
Search for more papers by this authorYildiz Yildirmak
Pediatric Hematology Division, Ministry of Health Sisli Etfal Education and Research Hospital, Istanbul, Turkey
Search for more papers by this authorOmer Dogru
Pediatric Hematology and Oncology Department, Marmara University School of Medicine, Istanbul, Turkey
Search for more papers by this authorTurkan Tansel
Istanbul Medical Faculty, Department of Cardiovascular Surgery, Istanbul University, Istanbul, Turkey
Search for more papers by this authorKhusan Khodzhaev
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
Institute of Health Sciences, Istanbul University, Istanbul, Turkey
Search for more papers by this authorOzlem Toluk
Department of Biostatistics and Medical Informatics, Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey
Search for more papers by this authorUgur Ozbek
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
Faculty of Medicine, Department of Medical Genetics, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
Search for more papers by this authorCorresponding Author
Muge Sayitoglu
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
Correspondence
Muge Sayitoglu, Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Vakif Gureba Cad. 34093, Istanbul, Turkey.
Email: [email protected]
Search for more papers by this authorAbstract
Introduction
The lymphoid enhancer factor 1 (LEF1) is a DNA-binding transcription factor that functions in the Wnt signaling pathway. Increased LEF1 activity is associated with progression of several types of cancer including leukemia. Here, we investigated LEF1 isoform expression and genomic variations in acute lymphoblastic leukemia (ALL).
Methods
LEF1 isoform expression was evaluated by quantitative real-time PCR in 87 newly diagnosed childhood ALL patients and controls. Moreover, Western blot analysis was performed for detection of LEF1 expression and the hotspot region of LEF1 was screened by deep sequencing.
Results
The LEF1 mRNA expression of B cell ALL patients was higher than the controls (LEF1-total P = .011, LEF1-long P = .026). Moreover, B-ALL samples showing higher total LEF1 expression had significantly shorter relapse-free survival (P = .008) and overall survival (P = .011). Although full-length LEF1 expression was similar to the controls in T-ALL, 50% (n = 15) of the ALL patients had increased full-length LEF1 protein expression. Imbalance between short- and full-length LEF1 isoforms may lead to cell survival in ALL. Beside the LEF1 activation, LEF1 gene variations were rarely observed in our cohort.
Conclusion
The results indicate that the Wnt pathway may have a pathogenic function in a group of ALL patients and high LEF1-total expression might be a marker for shorter relapse-free survival time in B cell ALL.
CONFLICT OF INTEREST
The authors declare no competing financial interests.
Open Research
DATA AVAILABILITY STATEMENT
Data available in article supplementary material. The data that supports the findings of this study are available in the supplementary material of this article
Supporting Information
| Filename | Description |
|---|---|
| ijlh13513-sup-0001-Supinfo.docxWord document, 5.6 MB | Supplementary Material |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015; 373(16): 1541-1552.
- 2Pui CH, Yang JJ, Bhakta N, Rodriguez-Galindo C. Global efforts toward the cure of childhood acute lymphoblastic leukaemia. Lancet Child Adolesc Health. 2018; 2(6): 440-454.
- 3Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003; 423(6938): 409-414.
- 4Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017; 169(6): 985-999.
- 5Ng OH, Erbilgin Y, Firtina S, et al. Deregulated WNT signaling in childhood T-cell acute lymphoblastic leukemia. Blood Cancer J. 2014; 4:e192.
- 6Staal FJ, Famili F, Garcia Perez L, Pike-Overzet K. Aberrant Wnt Signaling in Leukemia. Cancers (Basel). 2016; 8(9): 78.
- 7Wang YX, Zhang JH, Gu ZW. Wnt/beta-catenin signal pathway and malignant hematological disease – review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009; 17(1): 234-237.
- 8Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3): 469-480.
- 9Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012; 149(6): 1192-1205.
- 10Petropoulos K, Arseni N, Schessl C, et al. A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med. 2008; 205(3): 515-522.
- 11Gutierrez A, Tschumper RC, Wu X, et al. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood. 2010; 116(16): 2975-2983.
- 12Morgan RG, Ridsdale J, Payne M, et al. LEF-1 drives aberrant β-catenin nuclear localization in myeloid leukemia cells. Haematologica. 2019; 104(7): 1365-1377.
- 13Hovanes K, Li TW, Waterman ML. The human LEF-1 gene contains a promoter preferentially active in lymphocytes and encodes multiple isoforms derived from alternative splicing. Nucleic Acids Res. 2000; 28(9): 1994-2003.
- 14Hovanes K, Li TW, Munguia JE, et al. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet. 2001; 28(1): 53-57.
- 15Li TW, Ting JH, Yokoyama NN, Bernstein A, van de Wetering M, Waterman ML. Wnt activation and alternative promoter repression of LEF1 in colon cancer. Mol Cell Biol. 2006; 26(14): 5284-5299.
- 16Feder K, Edmaier-Schröger K, Rawat VPS, et al. Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis. Leukemia. 2020; 34(4): 1027–1037.
- 17Wang SH, Nan KJ, Wang YC, Wang WJ, Tian T. The balance between two isoforms of LEF-1 regulates colon carcinoma growth. BMC Gastroenterol. 2012; 12: 53.
- 18Gutierrez A, Sanda T, Ma W, et al. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 2010; 115(14): 2845-2851.
- 19Guo X, Zhang R, Liu J, et al. Characterization of LEF1 high expression and novel mutations in adult acute lymphoblastic leukemia. PLoS ONE. 2015; 10(5):e0125429.
- 20Kühnl A, Gökbuget N, Kaiser M, et al. Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia. Blood. 2011; 118(24): 6362-6367.
- 21Aly RM, Yousef AB. Prognostic significance of lymphoid enhancer-binding factor-1 expression in egyptian adult B-acute lymphocytic leukemia patients. Turk J Haematol. 2015; 32(1): 15-20.
- 22Staal FJ, Weerkamp F, Baert MR, et al. Wnt target genes identified by DNA microarrays in immature CD34+ thymocytes regulate proliferation and cell adhesion. J Immunol. 2004; 172(2): 1099-1108.
- 23Firtina S, Sayitoglu M, Hatirnaz O, et al. Evaluation of PAX5 gene in the early stages of leukemic B cells in the childhood B cell acute lymphoblastic leukemia. Leuk Res. 2012; 36(1): 87-92.
- 24Wang W, Ji P, Steffen B, et al. Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias. Acta Biochim Biophys Sin (Shanghai). 2005; 37(3): 173-180.
- 25Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6): 1101-1108.
- 26Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014; 11(4): 361-362.
- 27Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010; 7(4): 248-249.
- 28Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 2012; 40(W1): W452-W457.
- 29Zarrei M, MacDonald JR, Merico D, Scherer SW. A copy number variation map of the human genome. Nat Rev Genet. 2015; 16(3): 172-183.
- 30van de Wetering M, de Lau W, Clevers H. WNT signaling and lymphocyte development. Cell. 2002; 109(Suppl): S13-19.
- 31Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005; 434(7035): 843-850.
- 32Jia M, Zhao HZ, Shen HP, et al. Overexpression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in childhood acute lymphoblastic leukemia. Int J Lab Hematol. 2015; 37(5): 631-640.
- 33Wu W, Zhu H, Fu Y, et al. High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid. Oncotarget. 2016; 7(16): 21631-21643.
- 34Willinger T, Freeman T, Herbert M, Hasegawa H, McMichael AJ, Callan MF. Human naive CD8 T cells down-regulate expression of the WNT pathway transcription factors lymphoid enhancer binding factor 1 and transcription factor 7 (T cell factor-1) following antigen encounter in vitro and in vivo. J Immunol. 2006; 176(3): 1439-1446.
- 35Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446(7137): 758-764.
- 36Metzeler KH, Heilmeier B, Edmaier KE, et al. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood. 2012; 120(10): 2118-2126.
- 37Fu Y, Zhu H, Wu W, et al. Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia. Leuk Lymphoma. 2014; 55(2): 371-377.
Citing Literature
